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Introduction
Among the most aggressive and debilitating of all age-related movement disorders is the orphan disease called multiple system atrophy (MSA). MSA patients suffer debilitating parkinsonian, cerebellar, pyramidal, and autonomic symptoms (Fanciulli and Wenning, 2015; Jellinger, 2016; Stefanova and Wenning, 2016; Ubhi et al., 2011) . MSA pathology is associated with aSyn accumulation in the myelinating oligodendrocytes of the CNS (Ahmed et al., 2013; Fanciulli and Wenning, 2015; Papp et al., 1989; Stefanova and Wenning, 2016) . MSA-aSynaggregates in GCIs are linked to oligodendrocyte loss and demyelination (Dickson et al., 1999; Jellinger, 2014; Miller et al., 2004; Ubhi et al., 2011; Wakabayashi et al., 1998) . Symptoms similar to Parkinson's disease define parkinsonian type MSA (MSA-P), which manifests with rigidity, paralysis, and postural instability as well as striatonigral degeneration (SND). The cerebellar subtype called MSA-C primarily shows olivopontocerebellar atrophy (OPCA) and cerebellar ataxia. Both types of MSA exhibit cerebellar pathology (Ishizawa et al., 2004 ).
Autonomic problems are also common in all forms of MSA and include impaired sweating, as well as cardiovascular, sexual, urogenital, and gastrointestinal dysfunction (Coon et al., 2017; Jecmenica-Lukic et al., 2012; Jellinger, 2014; Jellinger et al., 2005; Kihara et al., 1991; Ubhi et al., 2011; Verstappen and Bloem, 2007) . Moreover, the myelinating glia of the peripheral nervous system, the Schwann cells (SC), contain aSyn cytoplasmic inclusions called SCCIs in cranial and spinal nerves, peripheral ganglia and the visceral autonomic innervation of MSA 4 becomes downregulated in oligodendrocytes when aSyn accumulates (May et al., 2014; SeguraUlate et al., 2017b) . A reduction in BDNF and GDNF also occurs in mice that overexpress aSyn under a myelin basic protein (MBP) promoter, the MBP-aSyn MSA mice (Ubhi et al., 2012; Ubhi et al., 2010) . GDNF delivery improves MBP-aSyn mouse movement (Ubhi et al., 2010) , as does fluoxetine, a drug that increases both BDNF and GDNF and reduces MSA-like motor impairment in MBP-aSyn mice (Ubhi et al., 2012 ). Yet, MBP-aSyn mice undergo almost no striatonigral degeneration, suggesting that their motor loss may be associated with brainstem, spinal cord, or cerebellar impairment. Another MSA model, mice that expresses aSyn in oligodendrocytes under the proteolipid protein (PLP) promoter (PLP-aSyn mice) (Kahle et al., 2002) show striatonigral degeneration that is common to MSA-P. Both MBP-aSyn and PLPaSyn mice model the progressive motor and autonomic dysfunction seen in MSA . Also, PLP-aSyn mice show microglial activation and brain GCI-like aSyn pathology (Stefanova et al., 2007) , as well as BDNF and GDNF changes that vary with age and CNS region (Refolo et al., 2018) . A third MSA model, the CNP-aSyn mice, though not as extensively studied as the MBP-aSyn and PLP-aSyn mice, also develops progressive motor and autonomic dysfunction as well as neuropil and white matter damage associated with aSyn pathology (Giasson et al., 2003; Yazawa et al., 2005) , as occurs in MSA-P and MSA-C patients (Minnerop et al., 2010) . Thus, though MSA models are imperfect, they still have predictive value for therapy development (Overk et al., 2018) . We obtained CNP-aSyn MSA mice in which to measure behavior, pathology, trophic factor expression, microglial activation, and responses to 3NP ± a FTY720-Mitoxy, measures not previously assessed in this model.
We have studied in vitro and in vivo effects of the parent compound FTY720
(fingolimod, Gilenya), an approved multiple sclerosis drug, on trophic factor expression. We and others show that FTY720 increases BDNF in cell and animal models (Deogracias et al., 2012; J o u r n a l P r e -p r o o f Journal Pre-proof Pardo et al., 2014; Doi et al., 2013; Fukumoto et al., 2014; Hait et al., 2014; Heinen et al., 2015; Noda et al., 2013; Schuhmann et al., 2016; Segura-Ulate et al., 2017b; Vargas-Medrano et al., 2014; Vidal-Martinez et al., 2016) . FTY720 also increases GDNF expression in astrocytes and microglia (Janssen et al., 2015; Noda et al., 2013) . However, FTY720 induces immunosuppression by interacting with sphingosine-1 phosphate receptors (S1PRs) to reduce circulating blood T cells (Ayzenberg et al., 2016; Chiba et al., 1998; Morris et al., 2005; Paugh et al., 2003) . As our derivative, FTY720-Mitoxy is not phosphorylated; it cannot modulate S1P receptors or alter T cell levels (Enoru et al., 2016; Segura-Ulate et al., 2017a; Segura-Ulate et al., 2017b; Vargas-Medrano et al., 2019) . While multiple sclerosis patients benefit from such immunosuppression and FTY720 might be repurposed to treat MSA, immunosuppression could be problematic when treating an aging disorder.
In addition to movement and autonomic dysfunction in MSA, is a finding of mitochondrial abnormalities. For instance, MSA skeletal muscle shows mitochondrial dysregulation (Blin et al., 1994) and there are losses in mitochondrial complex II and III activity in stem-cell-derived-dopaminergic-neurons from MSA patients (Alsemari and Al-Hindi, 2015; Monzio Compagnoni et al., 2018) . Also, MBP-aSyn mice show mitochondrial abnormalities in oligodendrocytes that are linked with aSyn aggregation (Overk et al., 2018; Shults et al., 2005) .
Notably, MSA models can also be generated using mitochondrial toxins. For example, 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) + 3NP induces MSA-like nigrostriatal and striatopallidal damage in 2 mo old WT mice (Stefanova et al., 2003) . In other models, symptomatic MBP-aSyn mice treated with 3NP have more severe motor loss and MSA-likeaSyn nitration/oxidation, while PLP-aSyn mice have increased microglial activation in cerebellar white matter (Stefanova et al., 2005; Ubhi et al., 2009) . With this in mind, we hypothesized that a therapy that can protect mitochondria and reduce microglial activation, as also occurs in MSA-J o u r n a l P r e -p r o o f
Journal Pre-proof P and MSA-C (Ishizawa et al., 2004) , may be especially beneficial for those with MSA. We created FTY720-Mitoxy by adding a triphenylphosphonium (TPP) moiety to the parent compound FTY720, to localize the derivative to presynaptic sites that are enriched in mitochondria (Chinnasamy et al., 2010; Vargas-Medrano et al., 2014; Zielonka et al., 2017) .
Over time we have confirmed that FTY720-Mitoxy rapidly crosses the blood brain barrier, increases neuronal BDNF expression, increases oligodendroglial GDNF, BDNF, and NGF expression and does not immunosuppress by reducing circulating T cells (Enoru et al., 2016; Segura-Ulate et al., 2017a; Vargas-Medrano et al., 2014; Vargas-Medrano et al., 2019) . As innervation of eccrine sweat gland utilizes GDNF, NGF as well as acetylcholine (Christianson et al., 2003; Grant et al., 1995; Landis et al., 1985; Yoshida, 2004) , we hypothesized that FTY720-Mitoxy's ability to increase trophic factor expression would improve sweat function (VargasMedrano et al., 2014; Vargas-Medrano et al., 2019) .
We tested FTY720-Mitoxy on MSA-like impairments in CNP-aSyn Tg mice that develop motor loss between 7 -9 mo (Yazawa et al., 2005) , similar to MBP-aSyn mice (6 mo), and earlier than PLP-aSyn mice (12 mo). We treated CNP-aSyn mice with FTY720-Mitoxy from 8.5 mo, and saw improved behavior. In addition, FTY720-Mitoxy reduced spinal cord aSyn aggregation and cerebellar white matter microglial activation. This occurred in parallel with frontal cortex/corpus callosum GDNF increase at both protein and mRNA levels and reduced expression of miR-96-5p, a microRNA that acts to downregulate GDNF (Alberico et al., 2015) .
In studies with the mitochondrial toxin 3NP, FTY720-Mitoxy reduced MSA-like-impairments in both WT and CNP-aSyn Tg mice by counteracting loss of succinate dehydrogenase (SDH; EC 1.5.3.1), mitochondrial Complex II activity. Cumulatively, these preclinical data support further testing of FTY720-Mitoxy as a candidate therapy for MSA and related synucleinopathies.
J o u r n a l P r e -p r o o f Journal Pre-proof
Materials and methods

Animals
CNP-aSyn (B6:C3-Tg-CNP-SNCA-M2Vle) breeders were generously provided by Dr.
Virginia Lee (University of Pennsylvania, Philadelphia, PA) (Giasson et al., 2003; Yazawa et al., 2005) from a repository at the Jackson Laboratories (Bar Harbor, ME). Non-littermate heterozygous CNP-aSyn breeders (N = 6, 4 females, 2 males) were used to generate our cohort of male and female Tg and WT littermates for our studies. Heterozygous and homozygous Tg mice express one or two copies of WT human SNCA, respectively, driven by the CNP promoter to express aSyn in myelinating oligodendrocytes of CNS and peripheral nervous system (PNS)
Schwann cells (Giasson et al., 2003; Yazawa et al., 2005 
Genotyping
Using the protocol kindly provided by Ms. Susan Leight of Dr. Virginia Lee's laboratory, genomic DNA from pups was used to measure human SNCA copy number by real time quantitative PCR (qPCR) with the following primersbicinchoninic acid (BCA) assay (Smith et al., 1985 was then measured relative to freshly prepared standards using the malachite green assay as before (Lek et al., 2017; Vargas-Medrano et al., 2014) with samples read at 630 nm (Multiskan Spectrum, ThermoFisher Scientific) (Fig. 1c) .
FTY720-Mitoxy, though not orally bioavailable, rapidly crosses the blood brain barrier (Enoru et al., 2016) which confirmed that intact FTY720-Mitoxy was present in mitochondria (Fig. 1b, bottom chromatogram).
Subcutaneous drug delivery by osmotic pump
FTY720-Mitoxy synthesis and pharmacokinetics have been described (Enoru et al., 2016; Vargas-Medrano et al., 2014) . Intravenously delivered FTY720-Mitoxy enters brain in 5 min and is present in brain for at least 48 hr (Enoru et al., 2016) . A stock solution of 150 mM FTY720-J o u r n a l P r e -p r o o f Journal Pre-proof 
Behavioral analysis
Behavioral tests were performed at 6 mo, 8 mo, 10 mo and 11.5 mo. Experiments were conducted in clean quiet test rooms at Texas Tech University Health Science Center Laboratory Animal Resources Center (LARC). Animals were transferred to test rooms at least 15 min before to allow them to acclimate to the novel environment prior to testing.
Movement
Balance, coordination and endurance were measured by rotarod (Cat # LE8200, Harvard Apparatus, Holliston, MA), which also measures endurance in N = 138 mice, (WT = 68, Tg = 70). Rotarod timing as "latency to fall" from the apparatus was recorded in sec using established methods (Giasson et al., 2002; Graham and Sidhu, 2010) . Briefly, mice were familiarized with the rotarod during initial trainings of 2 sessions on 2 consecutive days. Each training session consisted of 2 runs lasting 2 min each, one at 4 revolutions per min (rpm) and the other at 8 rpm.
Experimental data were collected in 3 runs/day on 2 different days for each mouse, with rotation increasing from 4-40 rpm over 5 min time. A minimum 5 min rest period was allowed between runs for all mice.
Sweat analysis
As a measure of autonomic injury of MSA, sweat droplets were measured by the method After the paw had dried, it was then painted with a starch solution prepared in castor oil (1g/mL, Cat # S9765 in Cat # 259853, Sigma-Aldrich, St. Louis, MO, USA). The paw was then photographed through a 10X magnifier lens at 0, 2.5 and 5 min to record dark purple precipitates that formed. Digital images were then blind coded and analyzed using ImageQuant 5.2 software (GE Healthcare, Waukesha, WI) to quantify sweat droplets in arbitrary units on the main area of the paw (outlined areas shown in Fig. 4a ) overlying the eccrine sweat glands. Sweat drops on the digits were not included in the quantification.
Evaluation of mitochondrial toxin 3NP ± FTY720-Mitoxy in WT and Tg mice
Osmotic pumps with FTY720-Mitoxy in Ringer's lactate delivered 1.1 mg/kg/day to 8. J o u r n a l P r e -p r o o f USA), an inhibitor of mitochondrial SDH, also known as mitochondrial Complex II (Scallet et al., 2001) , was prepared in sterile saline (pH 7.4). Vehicle consisted of an equal volume of sterile saline. On day 9.5, mice received twice daily subcutaneous injections of 3NP using methods previously used in MSA mice (Ubhi et al., 2009) as follows: 10 mg/kg (day 9.5), 20 mg/kg (days 11 and 12), and 30 mg/kg (days 13 and 14) or Vehicle control solution.
Tissue collection and handling
Mice were euthanized by CO 2 inhalation followed by decapitation. Tissues for protein and/or RNA were rapidly collected and included brain, spinal cord, paw sweat pads, and soleus muscles. Most tissues were frozen on dry ice then stored at -80°C until use. For total RNA, fresh tissues were submerged in RNA-later solution (Cat # AM7020, ThermoFisher Scientific) then incubated at 4°C overnight prior to transfer to -20°C for storage, as per manufacturer. Some RNA extractions were performed using tissues stored at -80°C, to which we added RNA-later-ICE (Cat # AM7030, ThermoFisher Scientific) followed by overnight incubation at -20°C before subsequent processing.
Gene and microRNA expression
Gene expression
Total mRNAs were extracted from brain and paw sweat glands using the RNeasy Plus Mini Kit (Cat # 74134, Qiagen Inc., Valencia, CA) then retrotranscribed using a High Capacity RNA-tocDNA Kit (Cat # 4387406, ThermoFisher Scientific), as per manufacturer. Total miRNAs from brain were extracted using the miRNeasy Mini Kit (Cat # 217004, Qiagen) according to the manufacturer. Retrotranscription of mature miRNAs was performed using the miScript II RT Kit (Cat # 218160, Qiagen). RNA concentration and purity were confirmed using NanoDrop 2000 spectrophotometry (ThermoFisher Scientific). Integrity of RNAs and assessment for genomic J o u r n a l P r e -p r o o f DNA contamination were done by evaluating 28S/18S rRNAs band ratios on RNA "bleach" gels as before (Aranda et al., 2012; Segura-Ulate et al., 2017b; Vargas-Medrano et al., 2018) . The mRNA and miRNA levels were measured by qPCR using the RealPlex Mastercycler 2 described above. Relative expression of mRNAs was evaluated using Taqman assays (ThermoFisher Scientific) for mouse BDNF (Cat # Mm04230607_s1), mouse NGF (Cat # Mm00443039_m1), mouse RET (Cat # Mm00436304_m1), and mouse GDNF (Cat # Mm00599849_m1), with mouse Gapdh (Cat # Mm99999915_g1) as an internal control. Reactions were carried out in triplicate using GoTaq Probe qPCR Master Mix (Promega, Cat # A6102).
MicroRNA expression
Relative expression of miR-96-5p was determined using miScript primer assays (Qiagen) for mature mm-miR-96-5p (Cat # MS00001456). Internal expression controls were performed with miScript primer assays for SNORD72 (Cat # MS00033719) and SNORD95 (Cat # MS00033726) and miScript miRTC (Cat # MS00000001) primer assay. Reactions were carried out in triplicate using the miScript Sybr Green qPCR Kit (Cat # 218075, Qiagen).
Mitochondria isolation
Brain mitochondria were isolated using a kit (Cat # 89801, ThermoFisher Scientific) according to the manufacturer. Protease inhibitors were added to all solutions, included 17 ug/mL aprotinin, 1 mM benzamidine, and 1 mM AEBSF. Dounce homogenization of 200 mg cerebellum/mouse was performed on ice to isolate mitochondria. The mitochondrial fraction was purified by centrifugation steps in which a final pellet containing mitochondria was suspended in 50 µl sterile PBS. Total protein concentration of isolated mitochondria was determined by BCA analysis described above.
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Succinate dehydrogenase assay of isolated mitochondria
SDH activity was measured using 60 µg of purified mitochondrial protein for all conditions using a colorimetric assay (Cat # MAK197-1KT, Sigma-Aldrich, St. Louis, MO USA). Briefly, mitochondria were added to the reaction mixture in a 96-well plate. Initial absorbance was measured at 600 nm at baseline (time 0), then again after 30 min incubation at 25 o C. SDH activity was determined relative to freshly prepared standards read at 600 nm in a plate reader (Multiskan Spectrum, ThermoFisher Scientific). The difference between the two readings was used to calculate SDH activity as defined in the kit protocol.
Protein assessments
Immunoblots
Protein concentrations were determined by BCA assay as described above. Proteins (25-50 μg per lane) were separated by SDS-PAGE, transferred to nitrocellulose, stained with Ponceau S to assess transfer, blocked with 5% non-fat dry milk in buffer 1 hr at room temperature, and incubated at 4°C in primary antibody overnight. For dot blots, equal protein amounts were applied to nitrocellulose with blots handled as described above. Blots were imaged using LiCor Odyssey (Model 9210, LiCor Biosciences, Lincoln, NE, USA) and quantified with LiCor Image Studio software or ImageQuant software (GE Healthcare Technologies, Waukesha, WI, USA).
Antibodies
Antibodies included: total aSyn (Cat # sc-7011-R, Santa Cruz Biotechnology Inc. Technology Inc., 1:1000). Infrared signals were produced using anti-mouse, anti-goat, or antirabbit secondary antibodies coupled to IgG IRDye680 or IgG IRDye800 (Rockland Immunochemicals, Gilbertsville, PA, USA, 1:5000 -1:10,000).
Sequential protein extractions
Please note that this method does not isolate cellular and subcellular fractions, but rather separates soluble from insoluble proteins in a series of buffers using ultracentrifugation for pellet re-extractions. Thus loading controls are unavailable when using this method. Protein extraction from lumbar spinal cord was performed according to Waxman and Giasson (2008) as detailed in Wu et al. (2012) and Vidal-Martinez et al. (Vidal-Martinez et al., 2016) . Soluble and insoluble proteins were isolated using a series of 4 buffers with pellets re-extracted after ultracentrifugation for 30 min at 100,000 x g (4 o C). Extraction buffers were: (1) high-salt (HS) containing 50 mM Tris-HCl (pH 8.0), 750 mM NaCl, and 5 mM EDTA; (2) high salt Triton X-100 (HST) containing 50 mM Tris-HCl (pH 8.0), 750 mM NaCl, 5 mM EDTA, (3) 1% Triton X-100; radioimmunoprecipitation assay buffer (RIPA) containing 50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 5 mM EDTA, 1% NP-40, 0.5% Sodium deoxycholate, and (4) 0.1% SDS; Sodium dodecylsulfate + Urea (SDS/Urea) containing 10 mM Tris-HCl (pH 7.5), 8 M Urea, 2% SDS.
Protease inhibitors included 17 µg/mL aprotinin, 1 mM benzamidine, and 1 mM AEBSF in all buffers.
Statistical analyses
Data represent mean ± standard deviation (SD) of 3 or more independent experiments.
Unpaired two-tailed Student's t-tests, One way ANOVA, or Two way repeated measures ANOVA were performed using Prism 8 (GraphPad Software Inc., La Jolla, CA) with significance set to p < .05. Linear regression was performed using GraphPad QuickCalcs.
J o u r n a l P r e -p r o o f
Relative mRNA or miRNA expression was calculated by the 2 -ΔΔCt method using Relative Expression Software Tool (REST-2009, Qiagen) (Pfaffl et al., 2002) . Whisker box plots generated with REST-2009, show relative mRNA or miRNA expression as median (dashed midline inside the box), interquartile ranges 1 and 3 (upper and lower edges of the box), and maximum and minimum expression values (top and bottom whiskers) (Pfaffl et al., 2002) . We are aware of growing concerns about the indiscriminate use of p values as the sole measure of statistical significance (Wasserstein et al., 2019) . Thus, we discuss why the differences found appear to be meaningful.
Results
FTY720-Mitoxy is stable in solution
Chemical structures of FTY720 and the FTY720-Mitoxy derivative are shown in Figure   1a . FTY720 parent compound is stable in solution (Morris et al., 2005 ), but we needed to ascertain if FTY720-Mitoxy was stable in solution and was present in mitochondria. To assess this we performed LC-MS/MS of fresh 1 µM FTY720-Mitoxy in solution ( FTY720-Mitoxy could be delivered by osmotic pump using the timeline shown (Fig. 1d) .
FTY720-Mitoxy counteracts motor deficits in aging CNP-aSyn Tg mice
Impaired motor function is seen in all MSA mice that express human aSyn in oligodendrocytes (Shults et al., 2005; Stefanova et al., 2005; Yazawa et al., 2005) . Measuring motor behavior by rotarod is an established method used to define both MSA-like onset and progression (Kuzdas-Wood et al., 2015; Shults et al., 2005; Yazawa et al., 2005) . In CNP-aSyn mice at 6 mo, we saw that rotarod performance was similar for both WT and CNP-aSyn Tg littermates (not shown) as previously confirmed (Yazawa et al., 2005) . By 8 mo, CNP-aSyn Tg mice had impaired rotarod performance compared to WT littermates (Fig. 2a) . Thus, we began delivering Vehicle or FTY720-Mitoxy by osmotic pump when mice were 8.5 mo old. It is noteworthy that CNP-aSyn Tg MSA mice that are untreated perform similarly on rotarod between 7 -12 mo (Yazawa et al., 2005) . We saw movement differences between treatment groups at 10 mo (One way ANOVA, Fig. 2b , p = .00009) and 11.5 mo (One way ANOVA, Fig.   2c , p = .00009). Tukey multiple comparisons showed that WT mice (N = 68) did similarly on rotarod at 10 mo when treated with Vehicle ( Fig. 2b ) ( ± SD = 90.44 ± 35.28 at 10 mo); or at 11.5 mo when treated with Vehicle ( Fig. 2c ) ( S = 87.8 ± 41.8 at 11.5 mo) or when treated with FTY720-Mitoxy (Fig. 2b , 10 mo) ( S = 93.97 ± 37.5 at 10 mo, p = .61, ns); or (Fig. 2c,   11 .5 mo) ( S = 91.6 ± 32.6 at 11.5 mo, p = .91, ns). In contrast, Vehicle treated CNP-aSyn Tg mice (N = 70) had poorer rotarod performance than Vehicle treated WT littermates (Fig. 2b, J o u r n a l P r e -p r o o f 10 mo) ( S = 79.37 ± 34.41, p = .014); or (Fig. 2c, 11 .5 mo) ( S = 76.4 ± 40.2, p = .039). After FTY720-Mitoxy, 10 mo and 11.5 mo CNP-aSyn Tg mice did significantly better than Vehicle treated Tg littermates (Fig. 2b , 10 mo) ( S = 99.22 ± 38.51, p = .00009); (Fig.   2c , 11.5 mo) S = 101.5 ± 45.9 at ll.5 mo, p = .00009) suggesting that motor deficits were reversed by FTY720-Mitoxy.
FTY720-Mitoxy contributes to increased soleus muscle weight in CNP-aSyn Tg mice
Muscle wasting occurs in MSA (Rehman, 2001 ). It has also been shown that mouse soleus muscle mass increases in parallel with rotarod performance (Yu et al., 2018) and that soleus muscles exhibit an oxidative metabolic phenotype with increased mitochondrial content (Crupi et al., 2018) . To further explore FTY720-Mitoxy effects in CNP-aSyn mice, we weighed soleus muscles of WT (N = 14) and Tg (N = 32) mice and discovered meaningful differences (Fig. 3 , One way ANOVA p = .046). Overall, soleus muscle weights were similar in WT Vehicle S = 9.9 ± 1.7), WT FTY720-Mitoxy S = 10.2 2.1), and Tg FTY720-Mitoxy treated mice S = 10.9 ± 2.6), though sizes overlap in all conditions. However, the MSAlike Vehicle treated CNP-aSyn Tg mice had significantly smaller soleus muscles than all others, as assessed by Tukey multiple comparisons S = 8.
1.2, p = .02). Smaller muscles in Tg
Vehicle treated mice related to their poorer rotarod performance, while increased soleus muscle mass in FTY720-Mitoxy treated Tg mice also related to their longer rotarod times (Fig. 2) .
FTY720-Mitoxy enhances sweat function and RET mRNA in CNP-aSyn Tg hind paw
MSA patients suffer from hypohidrosis or anhidrosis, a reduction or loss of the ability to sweat, especially in their lower extremities (Coon et al., 2017; Kihara et al., 1991; Lipp et al., 2009; Verstappen and Bloem, 2007) . However, the effect of a therapeutic on sweat production has never been tested in MSA mice. We measured hind paw sweat droplet signal by iodine-J o u r n a l P r e -p r o o f starch test with densitometry measured in arbitrary units (as detailed in Materials and methods) ( We next assessed trophic factor-related mRNAs to ascertain if FTY720-Mitoxy may have improved sweating in such a manner. We measured mRNA levels of GDNF, NGF, and RET (a GDNF receptor) in the sweat pads of representative WT (N = 8) and CNP aSyn Tg (N = 8) mice, as these factors contribute to sweat gland innervation. There was no difference in GDNF, NGF, or RET mRNAs in FTY720-Mitoxy treated WT mice relative to WT Vehicle Baseline (Fig. 4c ).
When we evaluated FTY720-Mitoxy treated CNP-aSyn Tg mice relative to WT Vehicle Baseline there also was no change in GDNF, NGF, or RET mRNA (Fig. 4d, left side) . In contrast, RET mRNA was significantly increased in the sweat pads of FTY720-Mitoxy treated CNP-aSyn Tg mice compared to Tg Vehicle Baseline (Fig. 4d , right side, p = .0008), suggesting that MSA-like autonomic sweating dysfunction was significantly improved by FTY720-Mitoxy.
FTY720-Mitoxy modulates GDNF and GDNF-associated miRNA in CNP-aSyn Tg brain
As mentioned above, we and others find that FTY720 reduces neurodegeneration by increasing BDNF in vitro and in vivo (Deogracias et al., 2012; Di Pardo et al., 2014; Doi et al., J o u r n a l P r e -p r o o f 2013; Efstathopoulos et al., 2015; Fukumoto et al., 2014; Hait et al., 2014; Heinen et al., 2015; Miguez et al., 2015; Noda et al., 2013; Potenza et al., 2016; Ren et al., 2017; Schuhmann et al., 2016; Segura-Ulate et al., 2017b; Vargas-Medrano et al., 2014; Vidal-Martinez et al., 2016) .
Similarly, FTY720 increases GDNF expression in glial cells (Janssen et al., 2015; Noda et al., 2013) . Moreover, BDNF and GDNF loss occurs in parallel with motor dysfunction in MBP-aSyn Tg brains (Ubhi et al., 2012; Ubhi et al., 2010) , and altered BDNF and GDNF expression also occurs in PLP-aSyn Tg brain (Refolo et al., 2018) . Regarding FTY720-Mitoxy, it can increase (Fig. 5b) .
The opposite has been shown for miR-96-5p, which is upregulated in human MSA and MBP-aSyn Tg brain , an upregulation that would decrease GDNF expression.
Remarkably, no evaluation of miR-96-5p or GDNF has been directly studied in the context of J o u r n a l P r e -p r o o f MSA, despite evidence that miR-96-5p regulates GDNF mRNA through octamer (8-mer) sequences with perfect complementarity in miR-96-5p and the G NF 3'-untranslated region 3'-UTR) (Kumar et al., 2015) (Fig. 5e) . We thus measured miR-96-5p in frontal cortex of Vehicle treated WT and Tg mice, and noted that baselines did not differ (Fig. 5d) , suggesting CNP-aSyn Tg mice do not suffer miR-96-5p dysregulation, consistent with their normal GDNF protein levels (Fig. 5b) . Nonetheless, in FTY720-Mitoxy treated Tg mice there was a significant decrease in miR-96-5p compared to WT baseline (Fig. 5d , left whisker box, p = .03) and to Tg baseline (Fig. 5d , right whisker box, p = .02). These findings appear to be meaningful and suggest that FTY720-Mitoxy may directly decrease miR-96-5p to increase GDNF mRNA and protein, which could be beneficial for MSA patients.
FTY720-Mitoxy reduces insoluble aSyn accumulation in CNP-aSyn Tg mice
As CNP-aSyn Tg mice express human WT aSyn only in myelinating cells (Yazawa et al., 2005), we were not surprised to find similar total aSyn protein levels when we evaluated representative WT (N = 3) and Tg (N = 6) lumbar spinal cords by immunoblot (Fig. 6a, 6b , One way ANOVA, p = .232, ns). Similar findings in these mice have previously been reported (Yazawa et al., 2005) . To assess pathological aSyn in lumbar spinal cord we sequentially extracted proteins (as detailed in Materials and methods) to isolate soluble aSyn in the first three buffers (HS, HST, and RIPA) and insoluble aSyn in the final buffer (SDS/Urea) of Vehicle and FTY720-Mitoxy treated mice using established methods (Lou et al., 2010; Vidal-Martinez et al., 2016; Wu et al., 2012) . Like Yazawa et al. (2005) , we also found insoluble monomeric aSyn in SDS-Urea extracts of lumbar spinal cord in WT and Tg mice (Fig. 6c , white boxed areas). As expected, insoluble aSyn levels were low in WT mice (Fig. 6c , WT Vehicle, 14.9 au) but we also found little insoluble aSyn in FTY720-Mitoxy treated Tg mice (Fig. 6c , Tg FTY720-Mitoxy, J o u r n a l P r e -p r o o f 12.8 au). In contrast, Vehicle treated Tg mice had 5 x more insoluble aSyn in lumbar spinal cord was soluble, suggesting that FTY720-Mitoxy has the capacity to reverse aSyn aggregation. We performed linear regression to compare aSyn pathology and sweat behavior in 11.5 mo mice and found that when aSyn aggregation increased in lumbar spinal cord, hind paw sweat function became more impaired revealing a significant negative correlation (Fig. 6d) .
Microglial activation in CNP-aSyn Tg cerebellum is reduced by FTY720-Mitoxy
In MSA, inflammation is associated with microglial activation as measured by the microglial marker Iba1 (Kiely et al., 2018; Raj et al., 2017; Waller et al., 2019; Xie et al., 2013) . As cerebellar pathology is also common in MSA (Ishizawa et al., 2004) , we assessed microglial activation in cerebellar white matter. On dot blots prepared from cerebellar white matter (Fig. 7a) we saw that WT Vehicle treated mice S = ANOVA, p = .0038). Similarly using Iba1 immunohistochemistry, we saw ramified processes on activated microglia in Vehicle treated Tg cerebellar white matter (Fig. 7 , bottom left) which was not seen in WT Vehicle (Fig. 7, top left) , WT FTY720-Mitoxy (Fig. 7, top right) , and FTY720-Mitoxy treated Tg littermates (Fig. 7, bottom right) . These findings show that FTY720-Mitoxy J o u r n a l P r e -p r o o f has potent anti-inflammatory effects in vivo, similar to our prior in vitro data with neuronal and oligodendroglial cell lines (Vargas-Medrano et al., 2014; Vargas-Medrano et al., 2019) .
FTY720-Mitoxy protects movement and mitochondria in the 3NP MSA mouse model
Cerebellum contributes to balance and coordination, which is often tested by rotarod. We (Fig. 8a , compare left and right graphs) as seen above in FTY720-Mitoxy treated Tg mice (Fig. 2b) .
J o u r n a l P r e -p r o o f
We also independently assessed SDH (Complex II) activity in mitochondria from WT and CNP-aSyn Tg mice. This was done using purified cerebellar mitochondria from representative WT (N = 3) and Tg mice (N = 3) to measure SDH activity in mitochondria from mice treated with Vehicle alone, 3NP alone, FTY720-Mitoxy + 3NP, or FTY720-Mitoxy alone.
SDH activity differences were seen for WT mice (Fig. 8b , left graph, One way ANOVA, p = .046). Tukey multiple comparisons confirmed that WT Vehicle SDH baseline S = .027 ± .004) was 3 x more active than 3NP alone WT mice S = .008 ± .003, p = .002), similar in FTY720-Mitoxy + 3NP doubly treated WT mice S = .031 ± .003, p = .77, ns) and also similar to FTY720-Mitoxy alone treated WT mice S = .031 ± .006, p = .72, ns).
Meaningful differences in mitochondrial SDH activity were also noted for CNP-aSyn Tg mice (Fig. 8b , right graph, One way ANOVA, p = .019). Vehicle treated Tg mice had mitochondrial SDH activity S = .0 3 ± .011) that was 3 x more active than 3 NP treated Tg mice SD = .014 ± .007, p = .045), similar to FTY720-Mitoxy + 3NP Tg doubly treated mice S = .029 ± .009, p = .42, ns) and similar to FTY720-Mitoxy Tg mice S = .058 ± .016, p = .31, ns). Taken together, the 3NP data suggest that FTY720-Mitoxy was able to protect both movement and mitochondria in WT and CNP-aSyn Tg mice.
Discussion
The Food and Drug Administration (FDA) Orphan Products Grants Program encourages development of drugs to treat orphan disorders such as MSA (Orphanet, ORPHA:102), and treatments that enhance trophic factor expression are considered to be broadly protective (Cai et al., 2014) . To this end, we created FTY720-Mitoxy and assessed its therapeutic potential using behavioral tests and evaluation of a variety of tissues from WT and CNP-aSyn Tg MSA mice.
FTY720-Mitoxy proved to be beneficial at counteracting several MSA-like impairments.
Importantly, WT and Tg mice treated with FTY720-Mitoxy showed no apparent adverse effects J o u r n a l P r e -p r o o f at doses comparable to those use with the parent compound FTY720. For further clarity regarding our findings, we also summarize the rationale for using various tissues and behaviors and related results in WT and Tg mice treated with FTY720-Mitoxy ( Table 1) .
As movement is impaired in humans suffering with MSA and also in MSA mouse models, we assessed WT and CNP-aSyn Tg mice rotarod performance before and after treating mice with Vehicle or FTY720-Mitoxy. We reconfirmed the findings of Yazawa et al. (2005) for 6 mo old WT and CNP-aSyn Tg mice, seeing similar rotarod performance at this stage (not shown). After FTY720-Mitoxy, Tg mice that had been impaired at 8 mo (Fig. 2a) were able to stay on the rotarod ~25% longer than their Vehicle treated Tg littermates by 10 -11.5 mo of age (Fig. 2b, 2c ). As muscle wasting is common in MSA (Rehman, 2001 ) and as exercise can increase soleus muscle mass (Sakakima et al., 2004) , we also compared soleus muscles in WT and Tg mice. FTY720-Mitoxy Tg mouse soleus muscles weighed ~20% more than soleus muscles from Vehicle treated Tg MSA littermates. FTY720-Mitoxy treated Tg mice also performed similarly to WT mice treated with Vehicle or FTY720-Mitoxy (Fig. 3) . Because FTY720-Mitoxy stimulates trophic factors expression, as does exercise (Cohen et al., 2003; Cotman and Berchtold, 2002; Smith and Zigmond, 2003) , we measured BDNF, GDNF, NGF, and RET (GDNF receptor) mRNAs in brain, in regions studied in MBP-aSyn MSA mice.
Although BDNF was unchanged (Supplemental Fig. S1 ), GDNF protein and mRNA were increased in frontal cortex of FTY720-Mitoxy treated Tg mice (Fig. 5a , 5b, 5c).
We also found that levels of miR-96-5p, a modulator of GDNF, were significantly reduced in FTY720-Mitoxy treated Tg mice (Fig. 5d) . As with other complementary mRNA/micro RNA interactions, as levels of miR-96-5p go down, levels of GDNF mRNA go up (Kumar et al., 2015) . We paid particular attention to miR-96-5p because its expression down-J o u r n a l P r e -p r o o f regulates GDNF (Kumar et al., 2015) and because miR-96-5p is upregulated in both human MSA and MBP-aSyn Tg mouse brains . As miR-96-5p contains a perfect 8-mer complementary sequence to the 3'-UTR of GDNF mRNA (Fig. 5e) , it typically induces GDNF mRNA degradation. Thus, reducing miR-96-5p likely explains our observed differences in GDNF mRNA and protein in CNP-aSyn Tg mice treated with FTY720-Mitoxy (Fig. 5a, b, c,   d ). The data suggest that FTY720-Mitoxy contributes to the decrease in miR-96-5p in Tg frontal cortex, which then led to an increase in GDNF expression. This may have occurred by FTY720-Mitoxy directly stimulating a mechanism called "target RNA-directed microRNA degradation"
(TDMD) (Fuchs Wightman et al., 2018) , although confirmation awaits further study.
Nonetheless, if individuals with MSA use a protective drug that can improve movement, muscle mass, and trophic factor expression it should be highly therapeutic.
Autonomic function is dysregulated in MSA, often leading to impaired sweat production and thermoregulation in MSA patients (Coon et al., 2017; Verstappen and Bloem, 2007) . As sweating has never been assessed in any MSA models in response to a potential therapeutic, we measured sweating in WT and CNP-aSyn Tg littermates treated with Vehicle or FTY720-Mitoxy. We saw that sweating was similar for Vehicle and FTY720-Mitoxy treated WT mice (Fig. 4b ), but significantly impaired in Vehicle treated Tg MSA mice, and significantly improved in Tg littermates treated with FTY720-Mitoxy (Fig. 4a, 4b) . During development GDNF, NGF and acetylcholine contribute to normal sweat pad innervation (Grant et al., 1995) and GDNF and the RET receptor are normally present in sweat gland (Yoshida, 2004) , thus we measured GDNF, NGF, and the RET receptor expression in sweat pads on the hind paw. There was no change in GDNF or NGF in WT or Tg mice, however, RET receptor mRNA was significantly increased in Tg mice after FTY720-Mitoxy (Fig. 4d) , which may have improved sweat gland GDNF signaling to improve sweating, although this also awaits confirmation. Yet, WT mice J o u r n a l P r e -p r o o f treated with FTY720-Mitoxy did not have increased sweating. Thus, a drug that normalizes sweat and thermoregulation for MSA patients should dramatically improve their quality of life.
Both motor and autonomic inputs to the hind limb pass through lumbar spinal cord.
Synucleinopathy has already been confirmed in the spinal cord of aging CNP-aSyn Tg mice (Yazawa et al., 2005) , thus, we measured pathological insoluble aSyn in Tg mice treated with
Vehicle or FTY720-Mitoxy. We found that the MSA-like Tg mice treated with Vehicle had 3 x more insoluble aSyn in lumbar spinal cord than their Tg littermates treated with FTY720-Mitoxy (Fig. 6c) . This suggests that FTY720-Mitoxy was able to reverse synucleinopathy, similar to our findings using the parent compound FTY720 in parkinsonian A53T Tg mice (Vidal-Martinez et al., 2016) . Because human aSyn expression in CNP-aSyn Tg mice is limited to myelinating oligodendrocytes primarily in the white matter, it was not surprising that aSyn protein levels were similar in frontal cortex of WT and CNP-aSyn Tg mice (Fig. 6a, b ) which contains abundant gray matter with endogenous mouse aSyn. However, when we isolated soluble and insoluble aSyn from spinal cord by sequential extraction, insoluble aSyn in SDS/Urea samples of CNP-aSyn Tg mice were highest for Vehicle treated Tg mice (Fig. 6c , middle group), findings that reiterate prior data in this model (Yazawa et al., 2005) . Additionally, insoluble aSyn levels were low in FTY720-Mitoxy treated CNP-aSyn Tg mice, similar to their age matched WT littermates (Fig. 6c , compare white boxed regions on aSyn blot). Based on these findings, we conclude that FTY720-Mitoxy reversed or prevented the progressive synucleinopathy in Tg Vehicle lumbar spinal cord from 8.5 -11. 5 mo. Identifying a therapeutic for MSA that will normalize aSyn solubility could be particularly protective.
We also showed in vivo that neuroinflammation in cerebellar white matter was reduced in Tg mice by FTY720-Mitoxy (Fig. 7) by measuring microglial activation associated with Iba1.
Thus, although we know that FTY720-Mitoxy is not immunosuppressive in the same manner at FTY720 (Segura-Ulate et al., 2017a), FTY720-Mitoxy did reduce microglia activation raising the possibility that FTY720-Mitoxy may positively regulate microglia-associated immune effects (Graeber and Streit, 2010; Schetters et al., 2018) . As microglial activation is very common in MSA, a drug that counteracts this type of neuroinflammation should be protective.
FTY720-Mitoxy was present in the mitochondrial sample as might be expected for a compound with a TPP modification (Fig. 1b, bottom chromatogram) (Zielonka et al., 2017) , though TPP compounds can also be found in cytosol (Filipovska et al., 2004) , and we have not ruled out if FTY720-Mitoxy may be present in other cellular compartments. To directly test FTY720-Mitoxy effects on mitochondria we evaluated SDH activity in mitochondria obtained from WT and CNP-aSyn Tg cerebellar white matter after treating with the mitochondrial toxin 3NP ± FTY720-Mitoxy. In those studies both WT and CNP-aSyn Tg mice treated with 3NP + FTY720-Mitoxy had preserved SDH activity, demonstrating the drug's ability to protect mitochondria (Fig. 8b) . As mitochondria are impaired in MSA, a drug that will protect these organelles should improve oxidative metabolism throughout the body to improve both CNS and PNS function.
Overall, FTY720-Mitoxy emerges as a potential MSA therapeutic that may improve motor function while decreasing synucleinopathy, increasing muscle mass and improving thermoregulation and sweat function. These beneficial effects were associated with reduced miR-96-5p expression and a corresponding increase in the potent neurotrophic molecule, GDNF.
Unlike FTY720, which causes overt immunosuppression by reducing circulating T lymphocytes in the blood (Brinkmann, 2009 ), FTY720-Mitoxy does not affect T cells (Segura-Ulate et al., 2017a) , thus making it a potentially safer option for aging disorders like MSA.
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